Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Under current guidance, women are referred for further investigation when their CA125 level reaches 35 IU/ml or above, ...

Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readinessCompany on track to initiate ...

The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...

Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...

The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...

Age based thresholds for blood tests to detect ovarian cancer should be introduced, the National Institute for Health and ...

Hormone therapy, also known as endocrine therapy, is a type of treatment your doctor may recommend as part of treatment for certain types of ovarian cancer, but not right away. Surgery is the first ...